Liver imaging
Bioxydyn uses dynamic gadoxetate-enhanced MRI to assess liver transporter function non-invasively, providing functional biomarkers of hepatocellular uptake and biliary excretion alongside complementary measures such as relaxation time mapping.
Transporters
Bioxydyn uses dynamic gadoxetate-enhanced MRI to assess liver transporter function non-invasively. Gadoxetate is taken up by functioning hepatocytes and excreted into bile, allowing MRI to measure key aspects of hepatobiliary transport in vivo. By combining dynamic imaging with quantitative modelling, we can derive biomarkers of hepatocellular uptake and biliary excretion, alongside complementary measures such as relaxation time mapping.
This approach provides functional information that cannot be obtained from standard anatomical imaging or blood measurements alone. It is particularly relevant where changes in liver transport may affect drug exposure, clearance, or tissue accumulation.
Drug safety
Liver transporter function is an important consideration in drug development, particularly for assessing drug-drug interaction risk and mechanisms that may contribute to drug-induced liver injury. Bioxydyn was the lead commercial partner in the IMI TRISTAN project, which investigated imaging biomarkers of liver and lung safety and supported the development of gadoxetate-based DCE-MRI biomarkers for DILI and DDI assessment.
Clinical translation
In a recent first-in-human study, dynamic gadoxetate-enhanced MRI detected drug-mediated inhibition of liver transporter function in healthy volunteers. Rifampicin reduced hepatocellular gadoxetate uptake by 93% and biliary excretion by 50% in participants who completed both study visits, supporting the use of these MRI-derived measures as non-invasive biomarkers of liver transporter inhibition in humans.